Olema Pharmaceuticals (OLMA) News Today

Acadian Asset Management LLC trimmed its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 59.7% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 103,179 shares of the company's stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) has been given an average recommendation of "Buy" by the seven brokerages that are currently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 1 year target price among

Olema Pharmaceuticals (NASDAQ:OLMA) Trading 6.7% Higher

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 6,380,000 shares, a decline of 18.0% from the June 15th total of 7,780,000 shares. Based on an average daily volume of 936,500 shares, the short-interest ratio is presently 6.8 days.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 5,000 shares of the firm's stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $12.26, for a total value of $61,300.00. Following the transaction, the director now directly owns 756,283 shares in the company, valued at $9,272,029.58. The sale was disclosed in a document filed with the SEC, which is available at this link.

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.6%

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 5%

Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 3.8%

Perceptive Advisors LLC acquired a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 539,831 shares of the company's stock, valued at

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 6.4%

First Light Asset Management LLC bought a new position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 631,064 shares of the company's stock,

Sectoral Asset Management Inc. lessened its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 95.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,230 shares of the company's stock after

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 3.2% After Insider Selling

Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12-month

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 5,000 shares of the company's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $10.93, for a total transaction of $54,650.00. Following the completion of the transaction, the director now owns 786,283 shares of the company's stock, valued at $8,594,073.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Olema Pharmaceuticals (NASDAQ:OLMA) Trading 9.2% Higher

HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Tuesday.

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $9.68

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Olema Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.50) pe

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.17

Victory Capital Management Inc. boosted its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 879.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 621,527 share

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 8th. Lifesci Capital analyst S. Slutsky forecasts that the

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 15,000 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total value of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares of the company's stock, valued at $7,715,301.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%